Loading company
Boundless Bio, Inc.
BOLD · Nasdaq · ·
Next earnings: November 4, 2026
$2.56-1.7%Sep 29 close
- 1M
- -9.5%
- 6M
- +135.9%
- 1Y
- +108.1%
- 5Y
- -95.7%
BOLD · Nasdaq · ·
Next earnings: November 4, 2026
$2.56-1.7%Sep 29 close
Boundless Bio, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$23.7M | -$15.7M | -51.15% |
| Profit per share | -$1.06 | -$0.70 | -51.43% |
| Free Cash Flow | -$21M | -$11.9M | -76.90% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Boundless Bio, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing BBI-940, a potentially first-in-class, oral, selective Kinesin degrader as an ecDNA-directed therapeutic candidate (ecDTx). Boundless Bio is headquartered in San Diego, California.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Boundless Bio, Inc.’s Item 2.02 8-K filed May 8, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.